Antidepressant Drugs Market to Surge at a Robust Pace by 2023 with top key players Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co.

Antidepressant Drugs Market by Depression Disorder, Product, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023," the antidepressant drugs market accounted for $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023. North America is the highest contributor in the antidepressant drugs market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Depression affects a person's thoughts, behavior, feelings and sense of well-being and is caused due to biological, genetics, environment, and psychological factors. The symptoms usually include low mood and aversion to physical activity. Depression is more common in women than men. Depression drugs works by fixing chemical imbalance such as lack of serotonin in the brain. Antidepressants helps in the treatment of depression by maintaining balance of various hormones and chemicals in the brain. Although effective treatments are available, many individuals with depression do not have access to treatment or do not take treatment, mainly due to lack of knowledge and social stigma.

Get sample copy of this report at:
www.alliedmarketresearch.com/request-sample/2593?utm_source=Prathm_OPR

Key Findings of the Antidepressant Drugs Market:

• Obsessive compulsive disorder is projected to grow at the highest rate during the analysis period.

• North America dominated global antidepressant drugs market in 2016, and is projected to continue its dominance in future.

• China is expected to grow highest in Asia-Pacific during the forecast period.

• Major depressive disorder is the largest contributor among the depressive disorder segments in 2016.

• Selective serotonin reuptake inhibitors segment generated the highest revenue, and is expected to continue its dominance in future.

In 2016, North America was the dominant revenue contributor, owing to the high prevalence rate of depression, presence of high disposable income, and increase in number of prescriptions for antidepressants. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to presence of populace countries such as India and China leading to large number of people suffering from depression and rise in healthcare expenditure.

Get customized copy of this report:
www.alliedmarketresearch.com/request-for-customization/2593?utm_source=Prathm_OPR

Key players:

• Alkermes Plc
• Allergan Plc
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• H. Lundbeck
• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.

Among the depressive disorder, major depressive disorder is the dominant segment as majority of the people are usually diagnosed with this disorder due to increase in stress levels. However, obsessive compulsive disorder is the fastest growing segment due to increase in the number of drugs for this disorder.

Table of content:

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis
3.4. Porter’s five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Increase in prevalence of depression
3.5.1.2. Rise in geriatric population
3.5.1.3. Increase in awareness towards depression

3.5.2. Restraints

3.5.2.1. Preference of non-pharmacological therapies over pharmacological therapies
3.5.2.2. Poor efficacy & safety profiles
3.5.2.3. Patent expiry of antidepressants leading to weak pipeline

3.5.3. Opportunity

3.5.3.1. Emergence of novel multimodal therapies

Access Full Summary at : www.alliedmarketresearch.com/antidepressants-drugs-market?utm_source=Prathm_OPR

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.